ArticleNeuro-oncology2021
TERT promoter mutation: is it enough to call a WHO grade II astrocytoma IDH wild-type glioblastoma?
Article in Neuro-oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Imaging diagnosis of adult-type diffuse gliomas in the era of WHO CNS5 and cIMPACT-NOW updates 8-11: a narrative review.Japanese journal of radiology · 2026Review
- Unraveling the heterogeneity of WHO grade 4 gliomas: insights from clinical, imaging, and molecular characterization.Discover oncology · 2025Article
- Diagnostic impact of DNA methylation classification in adult and pediatric CNS tumors.Scientific reports · 2025Article
- Histopathological grading affects survival in patients with isocitrate dehydrogenase-wildtype gliomas.Frontiers in oncology · 2025Article
- Unveiling divergent treatment prognoses in IDHwt-GBM subtypes through multiomics clustering: a swift dual MRI-mRNA model for precise subtype prediction.Journal of translational medicine · 2024Article
- Prognostic Impact ofCancers · 2024Article
- Surgical management and outcome of newly diagnosed glioblastoma without contrast enhancement (low-grade appearance): a report of the RANO resect group.Neuro-oncology · 2024Article
- Review
- Impact of new molecular criteria on diagnosis and survival of adult glioma patients.IBRO neuroscience reports · 2022Article
- Chromosomal instability in adult-type diffuse gliomas.Acta neuropathologica communications · 2022Review
- Grading of adult diffuse gliomas according to the 2021 WHO Classification of Tumors of the Central Nervous System.Laboratory investigation; a journal of technical methods and pathology · 2022Review
- Molecular Aberrations Stratify Grade 2 Astrocytomas Into Several Rare Entities: Prognostic and Therapeutic Implications.Frontiers in oncology · 2022Review
- Molecular testing for adolescent and young adult central nervous system tumors: A Canadian guideline.Frontiers in oncology · 2022Review
- GlioMarker: An integrated database for knowledge exploration of diagnostic biomarkers in gliomas.Frontiers in oncology · 2022Article
- Comparison of clinical, radiographic and genomic alterations between histologic and molecular glioblastoma,Neuro-oncology advancesArticle
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.